339 related articles for article (PubMed ID: 33839689)
21. KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras
Weng CC; Hawse JR; Subramaniam M; Chang VHS; Yu WCY; Hung WC; Chen LT; Cheng KH
Oncogene; 2017 Sep; 36(39):5532-5543. PubMed ID: 28581520
[TBL] [Abstract][Full Text] [Related]
22. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions.
Carrière C; Gore AJ; Norris AM; Gunn JR; Young AL; Longnecker DS; Korc M
Gastroenterology; 2011 Sep; 141(3):1091-101. PubMed ID: 21699781
[TBL] [Abstract][Full Text] [Related]
23. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
24. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
25. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
26. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
27. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
[TBL] [Abstract][Full Text] [Related]
28. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
29. p53 status determines the role of autophagy in pancreatic tumour development.
Rosenfeldt MT; O'Prey J; Morton JP; Nixon C; MacKay G; Mrowinska A; Au A; Rai TS; Zheng L; Ridgway R; Adams PD; Anderson KI; Gottlieb E; Sansom OJ; Ryan KM
Nature; 2013 Dec; 504(7479):296-300. PubMed ID: 24305049
[TBL] [Abstract][Full Text] [Related]
30. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
31. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
Gómez-Tomás Á; Pumarega J; Alguacil J; Amaral AFS; Malats N; Pallarès N; Gasull M; Porta M;
Environ Mol Mutagen; 2019 Oct; 60(8):693-703. PubMed ID: 31066938
[TBL] [Abstract][Full Text] [Related]
32. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
33. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
36. Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation.
Zhou X; Sun Z; Zhang M; Qu X; Yang S; Wang L; Jing Y; Li L; Deng W; Liu F; Di J; Chen J; Wu J; Zhang H
Animal Model Exp Med; 2022 Feb; 5(1):61-71. PubMed ID: 35229994
[TBL] [Abstract][Full Text] [Related]
37. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Fujimura K; Wang H; Watson F; Klemke RL
Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
[TBL] [Abstract][Full Text] [Related]
38.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract][Full Text] [Related]
39. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R; Annis J; Nikolova O; Whatcott C; Gurley K; Mendez E; Moran-Jones K; Dorrell C; Sears RC; Kuo C; Han H; Biankin A; Grandori C; Von Hoff DD; Kemp CJ
Cancer Res; 2022 Sep; 82(18):3375-3393. PubMed ID: 35819261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
